HealingWell
Search Close Search
☰

Another good Project Lyme interview - Monica Embers PhD

Support Forums
>
Lyme Disease
✚ New Topic ✚ Reply
❬ ❬ Previous Thread |Next Thread ❭ ❭
Posted 6/20/2024 11:28 AM (GMT -5)
as per the title

Monica Embers is a well respected researcher at Tulane University - who specialises in research of tick born infection in non-human animal models of disease

in recent years she has been funded by people like Bay Area Lyme, the Cohen foundation, as well as some limited funding from the US NIH - and had been trying to fill the gap in our knowledge around which combination antibiotics are effective in humans - or by nearest proxy - in non-human primates

https://www.youtube.com/watch?v=2lyr1m00qyy

this is very important work - as so far we only have mainly test tube based studies on antibiotic combination effectiveness - and we know that these test tube studies do not translate well to live animals or humans - because
the bacteria may exist in places inside the host that do not get the full concentration of antibiotics used in the test tube trials and because the bacteria themselves often adapt to the host environment in complex ways.
controlled trials are therefore needed to establish the best treatments

it was also encouraging to hear that her team are now also starting to focus on Bartonella
Posted 6/20/2024 4:02 PM (GMT -5)
Thanks Garzie. My doctor the other day was telling me he read a study saying chronic Lyme isn't real and then he was laughing...
I can email him this video.

I used AI for a summarization:


- Post-treatment Lyme disease syndrome (PTLDS) affects a significant number of patients, with symptoms persisting despite standard antibiotic treatment.

- Borrelia burgdorferi, the bacteria causing Lyme disease, can enter a "viable but non-culturable" (VBNC) state, making it difficult to detect and treat.

- Studies in animals (mice, dogs, and non-human primates) have shown persistence of B. burgdorferi after standard antibiotic treatments.

- Evidence of persistent infection has also been found in human patients, including detection of B. burgdorferi in brain and other tissues post-mortem.

- Combination antibiotic therapies have shown promise in eliminating persistent B. burgdorferi infections in animal studies, particularly when compared to monotherapy.

- Several combinations of FDA-approved drugs were successful in clearing persistent infections in mice, including doxycycline + ceftriaxone, dapsone + rifampin, and others.

- Human clinical trials of extended monotherapy have shown mixed results, with some improvements in fatigue and pain, but often not sustained long-term.

- Observational studies of combination therapies in humans have shown some promising results, but lack proper controls and randomization.

- Dr. Embers emphasizes the need for randomized controlled trials of combination therapies in patients with post-treatment Lyme disease.

- The presentation highlights the complexity of treating persistent Lyme disease and the importance of continued research in this area.
Posted 6/21/2024 6:36 AM (GMT -5)
that's a pretty good summary

the emphasis was on the need for actual large scale controlled trials of candidate combination antimicrobial treatments, such as those mentioned in the presentation, in humans with disseminated disease - ie chronic Lyme

as mice and humans are quite different in terms of drug pharmacokinetics and disease
Posted 6/25/2024 7:09 PM (GMT -5)
How do you use AI to get a summary on a youtube video/interview?

Vimzor said...
Thanks Garzie. My doctor the other day was telling me he read a study saying chronic Lyme isn't real and then he was laughing...
I can email him this video.

I used AI for a summarization:


- Post-treatment Lyme disease syndrome (PTLDS) affects a significant number of patients, with symptoms persisting despite standard antibiotic treatment.

- Borrelia burgdorferi, the bacteria causing Lyme disease, can enter a "viable but non-culturable" (VBNC) state, making it difficult to detect and treat.

- Studies in animals (mice, dogs, and non-human primates) have shown persistence of B. burgdorferi after standard antibiotic treatments.

- Evidence of persistent infection has also been found in human patients, including detection of B. burgdorferi in brain and other tissues post-mortem.

- Combination antibiotic therapies have shown promise in eliminating persistent B. burgdorferi infections in animal studies, particularly when compared to monotherapy.

- Several combinations of FDA-approved drugs were successful in clearing persistent infections in mice, including doxycycline + ceftriaxone, dapsone + rifampin, and others.

- Human clinical trials of extended monotherapy have shown mixed results, with some improvements in fatigue and pain, but often not sustained long-term.

- Observational studies of combination therapies in humans have shown some promising results, but lack proper controls and randomization.

- Dr. Embers emphasizes the need for randomized controlled trials of combination therapies in patients with post-treatment Lyme disease.

- The presentation highlights the complexity of treating persistent Lyme disease and the importance of continued research in this area.

✚ New Topic ✚ Reply